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OBJECTIVE—The G6PC2 gene encoding islet-speciﬁc glucose-
6-phosphatase related protein (IGRP) has a common promoter
variant, rs573225 (231G/A), located within a Foxa binding site.
We tested the cis-regulatory effects of rs573225 on promoter
activity and its association with insulin response to oral glucose.
RESEARCH DESIGN AND METHODS—Functional effects of
rs573225 were explored in transfected INS-1 and HIT-T -cell
lines. A total of 734 young obese subjects of European ancestry
were genotyped for rs573225. Insulin and glucose levels were
measured in response to oral glucose, and the insulinogenic
index (IGI) of insulin secretion was calculated.
RESULTS—In vitro, the G allele showed a higher afﬁnity for
binding Foxa2 transcription factor and increased G6PC2 pro-
moter activity. Foxa2 binding is modiﬁed if the C adjacent to the
G allele is methylated. IGI was associated with rs573225 by linear
regression analysis and was 30% greater in AA or AG than in GG
obese children. rs573225 was also associated with fasting
glucose.
CONCLUSIONS—rs573225 is a functional cis-regulatory (epi)-
single-nucleotide polymorphism (SNP) of G6PC2 associated with
glucose-insulin homeostasis in obese children, likely to explain
the results of recent genome-wide association studies in nondi-
abetic adults. Diabetes 58:489–492, 2009
T
he ﬂux through glycolysis is the sensed process
that makes -cells glucose responsive. Thus,
altered kinetics of glucose-induced insulin secre-
tion could result from a changed intrinsic activ-
ity, cellular level, or allosteric regulation of several
enzymes including glucokinase, phospho-fructokinase,
G6PC2 (glucose-6-phosphatase, catalytic, 2), or others
involved in the regulation of cellular glucose-6-phosphate
(G6P) content. Whereas glucokinase, a high Km enzyme,
phosphorylates glucose into G6P in -cells, G6PC2, a low
Km enzyme, catalyzes G6P dephosphorylation (1), which
could antagonize insulin secretion (2). In mice, G6PC2 has
only 5% of the activity of liver G6Pase (1), sufﬁcient
however for the knockout of G6PC2 to result in a small
decrease in glycemia (3). The human G6PC2 gene is
located in 2q24 in a region that we found linked to
glycemia (4). The G6PC2 promoter is inactive in HepG2
cells but has 150-fold more activity in HIT-T15 -cells, due
to the region located between 306 and 3 (5). This
proximal promoter region regulates G6PC2 expression in
transiently transfected TC-3, HIT-T15, and Min6 cells
through the binding of Foxa2 and MafA transcription
factors (6). We found three single-nucleotide polymor-
phisms (SNPs) in the G6PC2 promoter in public banks,
among which we selected rs573225, a G/A variant located
at position 231. Our choice was based on the fact that
this variant is common among European populations
and belongs to a binding site for Foxa transcription
factors (5,7) that carries a potentially methylatable CG
motif created by the G allele. The Foxa proteins, previ-
ously designated HNF-3, are known to modulate the
expression of pancreatic genes involved in glucose
homeostasis (8–11).
We performed a functional analysis of rs573225 in -cell
lines and found that this promoter SNP binds Foxa2 with
variable afﬁnity and can act as a transcriptional regulator
and then explored whether rs573225 genotypes were as-
sociated with insulin responses to oral glucose in 734
obese children of European ancestry. Recently, two inde-
pendent genome-wide association studies revealed that
SNPs in linkage disequilibrium with rs573225, but with no
known function, were associated with fasting glucose
levels in nondiabetic adults (12,13). We thus suspect
rs573225 to be the causative variant for the observed
associations.
RESEARCH DESIGN AND METHODS
Methylation-speciﬁc PCR. Human pancreatic DNAs were obtained from
human islets provided by T. Berney; 1 g was fragmented with XbaI and
denaturated by incubation in 3 mol/l NaOH for 15 min at 37°C. Bisulﬁte
conversion was carried out in a solution of sodium bisulﬁte and hydroquinone
at 55°C overnight. After desalting, DNAs were desulfonated by incubation in
NaOH at 37°C for 15 min, the solution was neutralized with Na-acetate, and
DNAs were ethanol precipitated. Pellets were dissolved in distilled H2O, and
DNA aliquots were used for PCR ampliﬁcations by TaqDNA polymerase
(Invitrogen) under the following conditions: 94°C, 5 min; 45 ampliﬁcation
cycles (94°C, 30 s; 50°C, 30 s; 72°C, 30 s); and ﬁnally at 72°C, 10 min. The PCR
products were puriﬁed using QIAquick kit (Qiagen) and used for automated
sequencing (DNA Sequencer, Roche).
Electrophoretic mobility shift assay. Nuclear extracts were prepared from
HepG2 cells using NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Pierce). Binding reactions used binding buffer with 1 l dIdC (Pierce). A total
of 4 g of the protein extracts was used per gel mobility shift sample.
Double-stranded oligonucleotides used to detect protein binding on the
G6PC2-231 element were end-labeled with biotin (Operon). The double-strand
oligonucleotides were “G” probe, 5-biotin-AATTTCAAGCAAACATGATC
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DIABETES, VOL. 58, FEBRUARY 2009 489CAACTGTT-3; “A” probe, 5-biotin-AATTTCAAACAAACATGATCCAACT
GTT-3; and “GC
m” probe, 5-biotin-AATTTCAAGC
MeAAACATGATCCA
ACTGTT-3. Samples were subjected to electrophoretic separation on a 6%
nondenaturating polyacrylamide gel. The gel was transferred to a Nylon
membrane (Pierce), which was cross-linked using a UV-Light cross linker
instrument (Bio-Rad) and incubated with Nucleic Acid Detection buffer
(Pierce). Signals were visualized using Chemiluminescent Substrate.
For supershift assays, binding reactions were incubated with 1 lo f
antibodies (Foxa 1, 2, or 3; Santa Cruz) before addition of biotin probes. DNA
protein complexes were electrophoresed through 6% nondenaturing poly-
acrylamide gel and revealed with the Nucleic Acid Detection Buffer.
Cell cultures. INS-1 cells derived from a rat insulinoma cell line developed
and propagated at the Division of Biochimie Clinique (C.B. Wollheim) were
cultured in RPMI-1640 media (GIBCO) with 10% heat-inactivated fetal bovine
serum (Dainippon Pharmaceutical), 50 mol/l 2-mercaptoethanol, 100
units/ml penicillin, and 0.1 mg/ml streptomycin. HIT-T15 cells were cultured in
the same media.
Transfections. We ampliﬁed the proximal promoter (306  14 bp) segment
of the human G6PC2 carrying either 231G or 231A allele. We inserted each
form into the pGl3 basic vector plasmid (Promega). Sequencing conﬁrmed
that constructs differed uniquely at the 231 position. A total of 100,000 INS-1
or HIT-T15 cells were plated on 24-well plates in RPMI-1640 (GIBCO) and
cotransfected with vector plasmids: 200 ng pGl3–231G or 231A per well and
70 ng pRL-TK plasmid (Promega) per well using Fugene HD (Roche).
Luciferase activities were determined 24 h after transfection using dual-
luciferase reporter assays (Promega) using a Centro LB 960 luminometer
(Berthold).
Cohort. The 734 studied obese children were recruited in the pediatric
endocrinology department of Saint Vincent de Paul Hospital as reported (4).
All were of Western European ancestry assessed by family history and
grandparents’ birthplace. Inclusion criteria were a BMI reaching the 95th
percentile at time of study, exceeding the 85th percentile before 6 years of age,
and a monotonic weight curve from birth to study time. After 12 h of overnight
fasting after 3 days of a standardized isocaloric diet, the oral glucose tolerance
test (OGTT) consisted of 1.75 g/kg glucose in 200 ml lemon-ﬂavored water at
10°C. Plasma insulin concentrations were measured in duplicate (14) at 0, 30,
60, 90, and 120 min. The insulinogenic index (IGI) was calculated as [Ins30 
Ins0 (pmol/l)]/[Gly30  Gly0 (mmol/l)], and homeostasis model assessment
(HOMA)- was calculated as [20  Ins0 (pmol/l)]/[Gly0 (mmol/l)] (14).
Genotyping. The rs573225 polymorphism was detected by ﬂuorescent hy-
bridization probe melting curves using real-time PCR. Samples were run on a
Roche LightCycler380; data were analyzed using LightCycler Software 3.5 (10
min denaturation; 40 cycles at 95°C, 1 s; 50°C, 5 s; 72°C, 15 s). Primer
sequences are available on request. Three internal controls made of samples
that were previously genotyped and sequenced were systematically intro-
duced into each 96-well plate.
Statistical analysis. Values are reported as means  SD. For all tests, a P
value 	0.05 was considered signiﬁcant. General linear regression models
were used to assess the relation between rs573225 and glucose or insulin
values. Regression model coefﬁcients were determined to be signiﬁcant with
the use of the standard t test. For glycemia and IGI analyses, the covariates
included age and BMI (15). Normality of residuals was systematically veriﬁed,
and robustness analyses were performed by dropping outliers from analyses.
For in vitro analyses, a t test was used to compare luciferase activity in the
genotypic groups for each cell type. Data analyses used the R statistical
software.
RESULTS
In vitro. We found that rs573225 alleles modiﬁed the
binding of Foxa to G6PC2 promoter by comparing the
binding of nuclear proteins from HepG2 cells to probes
carrying the “G” or the “A” allele or to a “GC
m” probe (Figs.
1 and 2). Electrophoretic mobility shift assay experiments
revealed that the G probe showed a speciﬁc binding to
HepG2 cell nuclear protein complex, whereas the A probe
could not bind this complex and the GC
m probe bound this
complex with a lower afﬁnity (Fig. 2A). The presence of
Foxa2 proteins in the DNA-protein complex was con-
ﬁrmed by gel supershift assay experiments (Fig. 2B).
These observations indicate that rs573225 alleles create a
functional variation in a Foxa2 binding motif, with an
added effect of the methylation of the cytosine residue
adjacent to the G allele of rs573225. When the proximal
segment of G6PC2 gene promoter bearing rs573225 and
placed upstream of the luciferase gene in the pGl3 basic
vector was transfected into INS-1 or HIT-T15 cells, the G
allele was consistently associated with a higher promoter
activity than the A allele (Fig. 2C).
In vivo. Our hypothesis that the candidate rs573225
variant was associated with parameters of insulin-glucose
homeostasis was supported by several ﬁndings (Table 1).
Linear regression analysis found that rs573225 was asso-
ciated with IGI (P 
 0.0191 under a recessive model and
P 
 0.0102 under an additive model). Indeed, IGI was
30% greater in these obese children with AA (36.8  38.1
mmol/l) or AG (33.5  24.2 mmol/l) genotypes compared
with GG homozygotes (21  16.9 mmol/l). Insulin levels
showed no signiﬁcant differences sensu stricto, but
showed a trend for higher insulin levels in obese children
of AA or AG genotype (P 
 0.058 for Ins0 and P 
 0.059 for
Ins30). In addition, linear regression analysis found that
rs573225 was associated with fasting glucose (P 
 0.032
under a recessive model and P 
 0.037 under an additive
model) with higher glucose levels in obese children with
AA or AG alleles.
DISCUSSION
When studied during their dynamic period of fat accumu-
lation, obese children have glucose-insulin homeostasis
yet are unaltered by dietary restriction or drugs, thus
allowing bona ﬁde genotype-phenotype studies. This pop-
ulation has the additional advantage of having normal
fasting glucose levels, which avoids the interference of
glucotoxicity with the studied -cell parameters. Obese
children oversecrete insulin in response to mounting insu-
lin resistance; thus, we could explore genotypic effects
over a wide range of insulin levels. Being aware that
insulin and glucose levels collected during OGTTs are not
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FIG. 1. Representative standard sequencing diagram for bisulﬁte di-
rect sequencing of G6PC2 gene promoter. Human pancreatic DNA
provided from a rs573225 heterozygote is shown. Signals of false
conversion were not observed. All cytosines in this sequence were not
converted to uracil. The G6PC2 gene promoter region was methylated.
On the bottom, the Foxa consensus site in humans is shown. (Please
see http://dx.doi.org/10.2337/db08-0587 for a high-quality digital repre-
sentation of this image.)
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mized stress and diet variations in controlled in-hospital
conditions. These strict criteria do not allow the study of
the thousands of subjects necessary to well-powered
association studies. We therefore consider our results as
tentative and needing further replication. Already, two
genome-wide association studies have reported the asso-
ciation of G6PC2 variants and fasting glycemia. In 9,353
normoglycemic subjects, Bouatia-Naji et al. (13) found an
association between fasting glycemia and rs560887. The
magnitude of the genotypic effect on glycemia was only
0.09 mmol/l, explaining why thousands of subjects were
necessary to reach signiﬁcance. Chen et al. (12) found a
signiﬁcant association between rs563694 and fasting glu-
cose in 5,088 nondiabetic individuals from Finland and
Sardinia and a P value of 5.7  10
7 for rs573225. Because
our rs573225 is in almost complete linkage disequilibrium
with rs560887 (r
2 
 0.96) and with rs563694 (r
2 
 0.95)
(according to the HapMap CEU reference panel), it is
likely that these three SNPs represent the same associa-
tion signal. Bouatia-Naji et al. (13) found an association
with the HOMA- index of insulin secretion derived from
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FIG. 2. The G allele of the rs573225 (231G/A) binds Foxa2 and is associated with increased transcriptional activity of the G6PC2 gene. A:
Electrophoretic mobility shift assay (EMSA) carried out with HepG2 nuclear extracts and unmethylated G probe or A probe and methylated CG
m
probe. The oligonucleotide sequence includes the G6PC2 promoter region 239 to 267. B: Speciﬁc antibodies was added in the gel supershift
assay and carried out with the G probe only. C: Mutation of the rs573225 G6PC2 promoter variant reduces G6PC2 transcriptional activity in
HIT-T15 cells (left) and in INS-1 cells (right). For each cell type, the following is shown: in gray, luciferase activity in pGl3 basic vector without
G6PC2 promoter (n  24); in black, luciferase activity in pGl3 basic vector with G6PC2 promoter bearing the 231A allele (n  24); and in white,
luciferase activity in pGl3 basic vector with G6PC2 promoter bearing the 231G allele (n  24). Data are means  SD. P  2.55  10
7 231G
allele vs. 231A allele, after Bonferroni correction.
TABLE 1
Clinical and biological characteristics of insulin secretion in
our young obese Caucasian cohort, according to rs573225
variant
G/G G/A A/A
n 60 293 381
Age (years) 12.4  2.8 11.8  3 11.7  2.8
BMI (kg/m
2) 30.7  5.6 29.7  5.3 29.6  5.5
Fasting glucose
(mmol/l) 4.41  0.51* 4.53  0.53 4.56  0.57
Glycemia at 30 min
(mmol/l) 7.47  1.22 7.67  1.23 7.53  1.3
Fasting insulin
(U/ml) 15  7.7 15.7  8.7 15.9  9.9
Insulin at 30 min
(U/ml) 87  52 109  77 106  85
IGI 21  16.9† 33.5  24.2 36.8  38.1
HOMA- 68.5  34.1 69.6  38.8 69.9  41.4
Data are means  SD. P values under a recessive model: *P 
 0.032
and P 
 0.037 under an additive model, †P 
 0.0191 under a
recessive model, and P 
 0.0102 under an additive model.
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found only an association of rs573225 with IGI, an index
derived from OGTT responses, not with HOMA-. IGI is an
index of insulin secretion that is based on the ﬁrst-phase
response to oral glucose and possibly more sensitive to
acute changes in -cell G6P level modulated by G6PC2
activity than is HOMA-. We suspect that these apparent
differences between results in large genome-wide associ-
ation studies and our candidate variant study may be due
to differences in sample size and nature of proxies used to
estimate insulin secretion.
Our functional analysis of the rs573225 variant in -cell
lines found that the G allele was able to bind Foxa2 factor
more efﬁciently than the A allele and was associated with
a higher G6PC2 promoter activity. Previous studies have
found that several mutated transcription factor sites lo-
cated in G6PC2 promoter could modify its expression
(6,17). Studies reviewed in Martin et al. (6) support a
positive role for Foxa2 in G6PC2 expression and a nega-
tive impact on insulin secretion in vitro (18–20). G6PC2
appears to negatively affect stimulus-secretion coupling
(3). Based on these studies and our own observations, we
postulate that the higher afﬁnity of Foxa factor for the G
allelic form of the binding promoter motif could result in
1) a higher expression of G6PC2, 2) a diminution of -cell
G6P content, and 3) a diminution of insulin secretion in
GG carriers. The cytosine adjacent to the G allele creates
a CG/CGm epi-allele that showed variable Foxa2 binding
capacity, which could possibly add allele-speciﬁc epige-
netic effects to the Foxa2-dependent transcriptional activ-
ity of the promoter. Rs573225 can thus be called an
epiSNP.
In summary, the present study reports that the G6PC2
promoter carries an rs573225 variant that modulates
Foxa2 binding and promoter activity and could inﬂuence
insulin secretion consistently with the known role of
G6PC2 in -cell physiology.
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